Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verucerfont. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 known ✓ | P34998 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verucerfont SCHEMBL1237818 | 1.00 | CRHR1 (1.00) | CRHR1 | |
| Verucerfont SCHEMBL205309 | 1.00 | CRHR1 (1.00) | CRHR1 | |
| Verucerfont SCHEMBL29482259 | 1.00 | CRHR1 (1.00) | CRHR1 | |
| Verucerfont SCHEMBL18407291 | 0.94 | CRHR1 (0.89) | CRHR1 | |
| SCHEMBL1236383 | 0.93 | CRHR1 (0.87) | CRHR1 | |
| SCHEMBL1237278 | 0.93 | CRHR1 (0.87) | CRHR1 | |
| SCHEMBL1237475 | 0.92 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL1236362 | 0.92 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL1236641 | 0.92 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL1237774 | 0.92 | CRHR1 (0.84) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802627-B1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2012-08-29 | — | — | EP | claimed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | claimed |
| EP-1802627-A1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044958-A1 | PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | claimed |
| US-20220211711-A1 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-07-07 | — | — | US | disclosed |
| US-20210038604-A1 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2021-02-11 | — | — | US | disclosed |
| US-10837062-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-11-17 | — | — | US | disclosed |
| US-20190194752-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-06-27 | — | — | US | disclosed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| US-10190168-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | HMNC VALUE GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| EP-1802627-B1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2012-08-29 | — | — | EP | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1802627-A1 | PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044958-A1 | PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194752-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | AVPR1B, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20150094310-A1 | CRHR1 ANTAGONISTS FOR USE IN THE TREATMENT OF PATIENTS HAVING CRH OVERACTIVITY | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20160153043-A1 | METHOD FOR PREDICTING A TREATMENT RESPONSE TO A CRHR1 ANTAGONIST AND/OR A V1B ANTAGONIST IN A PATIENT WITH DEPRESSIVE AND/OR ANXIETY SYMPTOMS | AVPR1B, CRHR1, AVPR1A | CRHR1 2/4885 |
| US-20210038604-A1 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | NR5A1, SHBG, CYP17A1 | CRHR1 50/4885 |
| US-10190168-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | AVPR1B, CRHR1, AVPR1A | CRHR1 2/4885 |
| US-10837062-B2 | Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms | AVPR1B, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20220211711-A1 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | NR5A1, SHBG, CYP17A1 | CRHR1 50/4885 |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.